Effects of β-blockers on the concentration and oxidizability of plasma lipids

Clinical Science

Volumn 94, Issue 6, 1998, Pages 573-578

  Dimmitt, Simon B ^a   Williams, Peta D ^a   Croft, Kevin D ^a   Beilin, Lawrence J ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Antioxidants; Coronary disease; High density lipoprotein; Low density lipoprotein; Oxidation; blockers

Indexed keywords

ALPHA TOCOPHEROL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA CAROTENE; CHOLESTEROL ESTER; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; PROPRANOLOL; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; HEART INFARCTION; HEART PROTECTION; HEART RATE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIPID OXIDATION; MALE; MORBIDITY; MORTALITY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 0031863262     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs0940573     Document Type: Article

References (25)

1. Kaplan JR, Manuck SB, Adams MR, Clarkson TB. (1987) The effects of beta-adrenergic blocking agents on atherosclerosis and its complications. Eur Heart J 8: 928-44.
2. Yusuf S, Wittes J, Friedman L. (1988) Overview of results of randomized clinical trials in heart disease: I. Treatments following myocardial infarction. JAMA 240: 2088-26-4.
3. Cruickshank JM, Smith JC. (1989) The beta-receptor, atheroma and cardiovascular damage. Pharmacol Ther 41: 385-404.
4. Ahmed R, Singh N. (1993) Antiarrhythmic drugs. Curr Opin Cardiol 8: 10-21.
5. Osborne JA, Stone PH. (1994) Recent advances in the understanding and management of stable and unstable angina pectoris and asymptomatic myocardial ischaemia. Curr Opin Cardiol 9: 448-56.
6. Ablad B, Bjorkman J-A, Gustafsson D, Hansson G, Ostlund-Lindqvist A-M, Pettersson K. (1998) The role of sympathetic activity in atherogenesis: effects of β-blockade. Am Heart J 116: 322-7.
7. Fitzgerald JD. (1987) By what means might beta blockers prolong life after acute myocardial infarction? Eur Heart J 8: 945-51.
8. Roberts WC. (1989) Recent studies on the effects of beta blockers on blood lipid levels. Am Heart J 117: 709-14.
9. Croft KD, Dimmitt SB, Moulton C, Beilin LJ. (1992) Low density lipoprotein composition and oxidizability in coronary disease - apparent favourable effect of beta blockers. Atherosclerosis 97: 123-30.
10. Esterbauer H, Striegl G, Puhl H, Rotheneder M. (1989) Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Rad Res Commun 6: 67-75.
11. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. (1989) Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320: 915-24.
12. Maziere C, Auclair M, Maziere J-C. (1992) Lipophilic β-blockers inhibit monocyte and endothelial cell-mediated modification of low density lipoproteins. Biochim Biophys Acta 1126: 314-18.
13. Yue T-L, McKenna PJ, Lysko PG, Ruffolo Jr RR, Feuerstein GZ. (1992) Carvedilol, a new antihypertensive, prevents oxidation of human low density lipoprotein by macrophages and copper. Atherosclerosis 97: 209-16.
14. Lesnik P, Dachet C, Petit L, et al. (1997) Impact of a combination of a calcium antagonist and a β-blocker on cell- and copper-mediated oxidation of LDL and on the accumulation and efflux of cholesterol in human macrophages and murine J774 cells. Arterioscler Thromb Vasc Biol 17: 979-88.
15. Friedewald WT, Levy RI, Fredrickson DS. (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultra-centrifuge. Clin Chem 18: 499-502.
16. Croft KD, Proudfoot J, Moulton C, Beilin LJ. (1991) The effect of lipoproteins on the release of some eicosanoids by stimulated human leukocytes. A possible role in atherogenesis. Eicosanoids 4: 75-81.
17. Croft KD, Beilin LJ, Vandongen R, Rouse I, Maserei J. (1990) Leukocyte and platelet function and eicosanoid production in subjects with hypercholesterolaemia. Atherosclerosis 83: 101-9.
18. Lang JK, Gohil K, Packer L. (1986) Simultaneous determination of tocopherols, ubiquinols and ubiquinones in blood, plasma, tissue homogenates and subcellular fractions. Anal Biochem 157: 106-16.
19. Lowry OH, Roseborough NJ, Farr AL, Randall RJ. (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-75.
20. Mak T, Weglicki WB. (1988) Protection by β-blocking agents against free radical-mediated sarcolemmal lipid peroxidation. Circ Res 63: 262-6.
21. Janero DR, Lopez R, Pittman J, burghardt B. (1989) Propranolol as xanthine oxidase inhibitor: implications for antioxidant activity. Life Sci 44: 1579-88.
22. Mogadam M, Ahmed SW, Mensch AH, Godwin ID. (1990) Within-person fluctuations of serum cholesterol and lipoproteins. Arch Intern Med 150: 1645-8.
23. Kubo M, Hosteller KY. (1987) Inhibition of purified bovine milk lipoprotein lipase by propranolol and other β-adrenergic blockers in vitro. Biochem Biophys Acta 918: 169-74.
24. 3-adrenergic receptor - a cause and cure of obesity? N Engl J Med 333: 382-3.
25. Lamont LS. (1995) Beta-blockers and their effects on protein metabolism and resting energy expenditure. J Cardiopulmonary Rehabil 15: 183-5.